Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:30AM ET
4.24
Dollar change
-0.10
Percentage change
-2.19
%
Index- P/E- EPS (ttm)-1.93 Insider Own27.84% Shs Outstand8.90M Perf Week-8.62%
Market Cap37.69M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.41M Perf Month16.16%
Income-16.97M PEG- EPS next Q- Inst Own10.48% Short Float2.34% Perf Quarter0.00%
Sales6.81M P/S5.54 EPS this Y- Inst Trans-44.97% Short Ratio6.11 Perf Half Y-10.55%
Book/sh1.58 P/B2.69 EPS next Y- ROA-57.38% Short Interest0.15M Perf Year402.79%
Cash/sh1.70 P/C2.49 EPS next 5Y- ROE-87.89% 52W Range0.67 - 9.68 Perf YTD-22.91%
Dividend Est.- P/FCF- EPS past 5Y52.24% ROI-120.75% 52W High-56.20% Beta1.50
Dividend TTM- Quick Ratio5.57 Sales past 5Y93.13% Gross Margin70.13% 52W Low532.27% ATR (14)0.31
Dividend Ex-Date- Current Ratio5.57 EPS Y/Y TTM46.20% Oper. Margin-211.77% RSI (14)47.99 Volatility8.79% 6.78%
Employees8 Debt/Eq0.00 Sales Y/Y TTM-24.43% Profit Margin-249.13% Recom1.00 Target Price40.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q32.93% Payout- Rel Volume0.21 Prev Close4.34
Sales Surprise- EPS Surprise- Sales Q/Q-68.07% EarningsNov 09 AMC Avg Volume24.52K Price4.24
SMA20-0.19% SMA50-0.10% SMA200-3.08% Trades Volume998 Change-2.19%
Date Action Analyst Rating Change Price Target Change
Mar-25-21Initiated Piper Sandler Overweight $6
Mar-19-21Initiated Cantor Fitzgerald Overweight $6
May-12-20Downgrade Piper Sandler Overweight → Neutral $5 → $2.50
May-30-19Initiated ROTH Capital Buy
Mar-01-19Initiated Janney Buy
Dec-03-18Upgrade Piper Jaffray Neutral → Overweight
Mar-25-24 05:45PM
Mar-22-24 12:30PM
Jan-22-24 07:30AM
Jan-08-24 09:31AM
08:24AM
11:00AM Loading…
Dec-21-23 11:00AM
Dec-11-23 07:00AM
Nov-09-23 05:00PM
Sep-11-23 07:00AM
Aug-30-23 08:00AM
Aug-25-23 12:07PM
Aug-17-23 09:03AM
Aug-14-23 04:30PM
Aug-07-23 07:00AM
Jul-26-23 07:00AM
08:12AM Loading…
Jul-22-23 08:12AM
Jul-10-23 07:00AM
Jun-26-23 07:00AM
Jun-12-23 07:00AM
May-31-23 06:30AM
May-17-23 06:11AM
May-08-23 07:30AM
May-01-23 07:30AM
Mar-22-23 08:10AM
Dec-13-22 07:23PM
07:00AM
Nov-22-22 07:28AM
07:00AM
Nov-10-22 05:35PM
04:05PM
07:00AM Loading…
Sep-13-22 07:00AM
Sep-08-22 07:00AM
Aug-11-22 04:22PM
Aug-04-22 04:37PM
Jun-15-22 07:06AM
May-13-22 07:00AM
May-04-22 10:30AM
Apr-26-22 07:00AM
Mar-17-22 05:45PM
Mar-07-22 04:05PM
Feb-17-22 01:08PM
Feb-16-22 04:30PM
Feb-08-22 04:05PM
Jan-20-22 06:38AM
Jan-19-22 04:49PM
Jan-06-22 08:53AM
Dec-31-21 09:40AM
Dec-09-21 07:00AM
Nov-18-21 04:05PM
Nov-10-21 04:05PM
Oct-08-21 09:24AM
Sep-07-21 04:05PM
Aug-20-21 12:00PM
Aug-19-21 04:05PM
Aug-10-21 04:01PM
Aug-09-21 06:57AM
Jul-28-21 04:05PM
Jul-06-21 07:00AM
Jun-29-21 09:01AM
Jun-16-21 04:05PM
May-20-21 04:06AM
May-12-21 04:05PM
02:45PM
Apr-29-21 04:05PM
Apr-27-21 07:41PM
Apr-08-21 03:23PM
Apr-07-21 08:32AM
Mar-16-21 04:57PM
Mar-15-21 07:00AM
Mar-12-21 08:00AM
Mar-11-21 04:10PM
Mar-09-21 04:12PM
Mar-03-21 07:00AM
Mar-01-21 05:03AM
Jan-13-21 07:00AM
Jan-05-21 07:00AM
Nov-30-20 02:30AM
Nov-09-20 04:01PM
03:15PM
Nov-02-20 07:00AM
Sep-17-20 07:00AM
Aug-10-20 04:00PM
Jun-30-20 07:00AM
Jun-23-20 07:00AM
Jun-10-20 02:14PM
Jun-02-20 06:34AM
May-29-20 08:00AM
May-13-20 05:01PM
May-11-20 04:05PM
May-04-20 04:05PM
Apr-30-20 12:32PM
Apr-29-20 04:05PM
Apr-11-20 01:59PM
Apr-10-20 06:24PM
Mar-12-20 04:01PM
Mar-02-20 07:00AM
Feb-18-20 07:00AM
Feb-11-20 07:00AM
Jan-06-20 10:01AM
Dec-17-19 05:45PM
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.